You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
晨光生物(300138.SZ):前三季度淨利潤預增17.00%至20.26%
格隆匯 10-10 18:16

格隆匯10月10日丨晨光生物(300138.SZ)公佈2023年前三季度業績預吿,報吿期歸屬於上市公司股東的淨利潤盈利39,400萬元—40,500萬元,比上年同期增長17.00%至20.26%;歸屬於上市公司股東扣除非經常性損益後的淨利潤盈利32,000萬元—33,100萬元比上年同期增長6.73%至10.40%。

其中,第三季度歸屬於上市公司股東的淨利潤盈利9534.56萬元—10,634.56萬元,比上年同期增長-1.06%至10.36%;歸屬於上市公司股東扣除非經常性損益後的淨利潤盈利8421.21萬元—9521.21萬元,比上年同期增長-4.68%至7.77%

。2023年前三季度公司主要產品辣椒紅色素、食品級葉黃素和香辛料提取物銷量和收入同比增長,其他潛力品種持續提升,公司業績同比增長。經初步測算,預計2023年前三季度實現歸屬於上市公司股東的淨利潤39,400萬元—40,500萬元,同比增長17.00%至20.26%,其中非經常性損益影響金額約7400萬元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account